Characterization of GBM Patient-Derived Cell Lines

We have developed a characterised GBM patient-derived cell line resource (Q-Cell) [10 (link),11 (link),12 (link),13 (link)], in which lines are maintained as glioma neural stem cell (GNS) cultures [14 (link)] or as 3D neurosphere cultures [15 (link)] using StemPro NSC SFM (Invitrogen, Carlsbad, CA, USA) or KnockOut™ DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) as per the manufacturer’s guidelines. Characterisation data is freely available from https://www.qimrberghofer.edu.au/q-cell/. All tissues were collected following ethical approval from the Royal Brisbane Women’s Hospital and QIMR Berghofer Human Research Ethics Committees. Ethical approval number: P3420, HREC/17/QRBW/577 Novel Therapies for Brain Cancer. In order to maintain pluripotency, KnockOut™ DMEM (Gibco) media were supplemented with GlutaMAX™ Supplement (Gibco), StemPro™ Neural Supplement (Gibco), Recombinant Human EGF (Gibco), Recombinant Human FGFb (Gibco), and Penicillin/Streptomycin (Gibco). Cells were cultured on flasks coated with Basement Membrane Matrigel® Matrix (Corning, New York, NY, USA). Passaging the cells was done by detaching the cells from the flask surface using Accutase® solution (Sigma-Aldrich, St. Louis, MO, USA). Glioma cells were cultured as glioma neural stem (GNS) cultures as outlined in detail in [14 (link)] or as tumourspheres using StemPro^® NSC SFM.